Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib in Cutaneous Squamous Cell Carcinoma
NCT01666431Phase 2Terminated
- Sponsor
- University of Zurich
- Start
- Jun 2012
- Primary completion
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lapatinib in squamous cell carcinoma of the skin (cSCC) and actinic keratosis (AK), sponsored by University of Zurich. Primary endpoint: Macroscopic evaluation of tumour response at 84 days. Started Jun 2012; status: terminated.
02
Drugs
lapatinib
03
Conditions
squamous cell carcinoma of the skin (cSCC)actinic keratosis (AK)
Beyond the preview
Go deeper on NCT01666431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01666431.